Programmed oral delivery of peptide therapeutics for multiorgan targeting in metabolic disorders of hyperglycemia and hyperuricemia
Science Advances · 12.06.2026 · 12 (24)
DOI: 10.1126/sciadv.aef3323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 12.06.2026. Verfasst von Junyu Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China. Hauptthemen laut MEDLINE: Hyperuricemia, Peptides, Hyperglycemia, Drug Delivery Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Guangdong Provincial Pearl River Talents Program, Tsinghua Shenzhen International Graduate School, National Natural Science Foundation of China.
Abstract (Originalsprache)
Systemic metabolic disorders such as diabetes and hyperuricemia demand multiorgan therapeutic intervention, yet single-target therapies often fail to restore homeostasis. Here, we present an orally administered, multistage-targeted nanoplatform (P1P2NPs) for the sequential delivery of therapeutic peptides to distinct organs. P1P2NPs is composed of a bioresponsive polymer poly(β-amino ester)-disulfide bond-poly(carboxybetaine) (PAE-SS-PCB), 1,2-distearoyl- sn -glycero-3-phosphoethanolamine-block poly(carboxybetaine) (DSPE-PCB) and Eudragit L100-55, designed to release peptide P2 (Val-Pro-Tyr-Pro-Gln) in the intestine for dipeptidyl peptidase-IV (DPP-IV) inhibition, while hepatic-targeted peptide P1(Pro-Pro-Lys-Asn-Trp) is selectively liberated in the liver to suppress xanthine oxidase (XOD). Fabricated through sequential emulsification and layer-by-layer assembly, P1P2NPs exhibit spatiotemporal control over drug release, enabling precise modulation of intestinal and hepatic metabolic pathways. In a murine model of diabetic-hyperuricemia comorbidity, the nanoplatform demonstrated synergistic efficacy by normalizing glucose and uric acid levels through multiorgan targeting. This work establishes a paradigm for spatially controlled peptide delivery, offering a versatile strategy for treating complex metabolic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
- Key Laboratory of Bioactive Proteins and Peptides Green Biomanufacturing of Guangdong Higher Education Institutes, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
- Institute of Biochemical Engineering, Department of Chemical Engineering, Tsinghua University, Beijing 100084, China.
- Key Laboratory of Industrial Biocatalysis, Ministry of Education, Tsinghua University, Beijing 100084, China.
ORCID-Profile: Junyu Liu, Xupu Xing, Chang Wen, Yuqing Huang, Yi Wang, Xin-Hui Xing, Can Yang Zhang
Förderung
- Guangdong Provincial Pearl River Talents Program
- Tsinghua Shenzhen International Graduate School
- National Natural Science Foundation of China
- Key Research and Development Program of the Ministry of Science and Technology
- Shenzhen Technology and Innovation Commission
- Shenzhen Medical Research Fund
Zitieren
APA
Liu, J., Xing, X., Wen, C., Chen, H., Li, W., Huang, Y., Wang, Y., Xing, X. H., & Zhang, C. Y. (2026). Programmed oral delivery of peptide therapeutics for multiorgan targeting in metabolic disorders of hyperglycemia and hyperuricemia. Science Advances, 12(24). https://doi.org/10.1126/sciadv.aef3323
Vancouver
Liu J, Xing X, Wen C, Chen H, Li W, Huang Y, et al. Programmed oral delivery of peptide therapeutics for multiorgan targeting in metabolic disorders of hyperglycemia and hyperuricemia. Science Advances. 2026;12(24). doi:10.1126/sciadv.aef3323
BibTeX
@article{Liu2026,
author = {Liu, Junyu and Xing, Xupu and Wen, Chang and Chen, Haihong and Li, Wei and Huang, Yuqing and Wang, Yi and Xing, Xin-Hui and Zhang, Can Yang},
title = {Programmed oral delivery of peptide therapeutics for multiorgan targeting in metabolic disorders of hyperglycemia and hyperuricemia},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {24},
doi = {10.1126/sciadv.aef3323}
}
EUVIMED